WO2002009686A3 - Inhibiteurs de phosphatases cdc25 - Google Patents

Inhibiteurs de phosphatases cdc25 Download PDF

Info

Publication number
WO2002009686A3
WO2002009686A3 PCT/FR2001/002443 FR0102443W WO0209686A3 WO 2002009686 A3 WO2002009686 A3 WO 2002009686A3 FR 0102443 W FR0102443 W FR 0102443W WO 0209686 A3 WO0209686 A3 WO 0209686A3
Authority
WO
WIPO (PCT)
Prior art keywords
radical
alkyl
hydrogen atom
independently
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2001/002443
Other languages
English (en)
Other versions
WO2002009686A2 (fr
Inventor
Gregoire Prevost
Pannetier Marie-Christi Brezak
Contour Marie-Odile Galcera
Christophe Thurieau
Francoise Goubin-Gramatica
Bernard Ducommun
Christophe Lanco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP01960837A priority Critical patent/EP1370255A2/fr
Priority to PL01365074A priority patent/PL365074A1/xx
Priority to HK04105845.2A priority patent/HK1063016B/xx
Priority to HU0303828A priority patent/HUP0303828A3/hu
Priority to US10/343,171 priority patent/US7196084B2/en
Priority to CA002417262A priority patent/CA2417262A1/fr
Priority to AU8223401A priority patent/AU8223401A/xx
Priority to BR0112824-8A priority patent/BR0112824A/pt
Priority to IL15399901A priority patent/IL153999A0/xx
Priority to NZ523739A priority patent/NZ523739A/en
Priority to AU2001282234A priority patent/AU2001282234B2/en
Priority to MXPA03000860A priority patent/MXPA03000860A/es
Priority to JP2002515239A priority patent/JP2004506618A/ja
Priority to KR10-2003-7001208A priority patent/KR20030020414A/ko
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Publication of WO2002009686A2 publication Critical patent/WO2002009686A2/fr
Priority to IL153999A priority patent/IL153999A/en
Priority to NO20030421A priority patent/NO20030421L/no
Priority to IS6701A priority patent/IS6701A/is
Anticipated expiration legal-status Critical
Publication of WO2002009686A3 publication Critical patent/WO2002009686A3/fr
Priority to US11/350,692 priority patent/US20060154933A1/en
Priority to US11/410,659 priority patent/US20060235027A1/en
Priority to AU2006233164A priority patent/AU2006233164B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

L'invention a pour objet de nouveaux inhibiteurs de phosphatases cdc25, et en particulier de phosphatase cdc25-C, lesquels répondent à la formule générale (I) dans laquelle A représente un radical aryle carbocyclique éventuellement substitué de 1 à 3 fois par un ou des radicaux choisis indépendamment parmi un atome halogène et un radical alkyle, hydroxy, alkoxy, alkylthio ou NR1R2 dans lequel R1 et R2 représentent un atome d'hydrogène ou un radical alkyle ou R1 et R2 forment ensemble avec l'atome d'azote un hétérocycle de 4 à 7 chaînons comportant de 1 à 2 hétéroatomes, les chaînons nécessaires pour compléter l'hétérocycle étant choisis indépendamment parmi les radicaux CR3R4-, -O-, -S- ET NR?5-, R3 et R4¿ représentant indépendamment à chaque fois qu'ils interviennent un atome d'hydrogène ou un radical alkyle, hydroxy, alkoxy, amino, alkylamino ou dialkylamino, et R5 représentant indépendamment à chaque fois qu'il intervient un atome d'hydrogène ou un radical alkyle, ou encore A représente un radial phényle substitué par un radical phényle éventuellement substitué de 1 à 3 fois par un ou des radicaux choisis indépendamment parmi un atome halogène ou un radical alkyle, hydroxy, alkoxy, alkylthio ou NR1R2 dans lequel R1 et R2 représentent un atome d'hydrogène ou un radical alkyle; B représente un radical (CH¿2?)q- ou (CH2)j-CO-(CH2)n- ou-(CH2)p-, I et n étant des entiers de 0 à 2 et p étant un entier de 0 à 1; W représente un atome d'hydrogène ou un radical alkyle; X représente un radical -(CH2)q- ou -(CH2)j-CO-(CH2)r-, q étant un entier de 1 à 4 et j et r étant des entiers de 0 à 6; Y représente notamment un radical nitrophényle. Aminophényle, alkylaminophényle ou dialkylaminophényle ou encore le radical (T) représenté ci-dessous.
PCT/FR2001/002443 2000-07-28 2001-07-26 Inhibiteurs de phosphatases cdc25 Ceased WO2002009686A2 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
JP2002515239A JP2004506618A (ja) 2000-07-28 2001-07-26 Ｃｄｃ２５ホスファターゼ阻害剤
HK04105845.2A HK1063016B (en) 2000-07-28 2001-07-26 Cdc25 phosphatase inhibitors
HU0303828A HUP0303828A3 (en) 2000-07-28 2001-07-26 Cdc25 phosphatase inhibitors, process for their preparation and their use for preparation of pharmaceutical compositions
US10/343,171 US7196084B2 (en) 2000-07-28 2001-07-26 Cdc25 phosphatase inhibitors
CA002417262A CA2417262A1 (fr) 2000-07-28 2001-07-26 Inhibiteurs de phosphatases cdc25
AU8223401A AU8223401A (en) 2000-07-28 2001-07-26 Cdc25 phosphatase inhibitors
PL01365074A PL365074A1 (en) 2000-07-28 2001-07-26 Cdc25 phosphatase inhibitors
IL15399901A IL153999A0 (en) 2000-07-28 2001-07-26 Cdc25 phosphatase inhibitors
NZ523739A NZ523739A (en) 2000-07-28 2001-07-26 CDC25 phosphatase inhibitors
AU2001282234A AU2001282234B2 (en) 2000-07-28 2001-07-26 CDC25 phosphatase inhibitors
MXPA03000860A MXPA03000860A (es) 2000-07-28 2001-07-26 Inhibidores de cdc25-fosfatasas.
EP01960837A EP1370255A2 (fr) 2000-07-28 2001-07-26 Inhibiteurs de phosphatases cdc25
BR0112824-8A BR0112824A (pt) 2000-07-28 2001-07-26 Utilização de um composto ou de um sal farmaceuticamente aceitável do mesmo, medicamento, composto, composição farmacêutica, e, processo de preparação de um composto
KR10-2003-7001208A KR20030020414A (ko) 2000-07-28 2001-07-26 Ｃｄｃ25 포스파타제 억제제
IL153999A IL153999A (en) 2000-07-28 2003-01-16 Preparations for inhibiting 5CDC 2 phosphatases, compounds for these preparations and methods for their preparation
NO20030421A NO20030421L (no) 2000-07-28 2003-01-27 Inhibitorer av Cdc25 fosfataser
IS6701A IS6701A (is) 2000-07-28 2003-01-27 Cdc25 fosfatasahemlar
US11/350,692 US20060154933A1 (en) 2000-07-28 2006-02-09 Inhibitors of Cdc25 phosphatases
US11/410,659 US20060235027A1 (en) 2000-07-28 2006-04-25 Inhibitors of cdc25 phosphatases
AU2006233164A AU2006233164B2 (en) 2000-07-28 2006-10-24 Inhibitors of Cdc25 phosphatases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR00/09900 2000-07-28
FR0009900A FR2812198B1 (fr) 2000-07-28 2000-07-28 DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/350,692 Division US20060154933A1 (en) 2000-07-28 2006-02-09 Inhibitors of Cdc25 phosphatases
US11/410,659 Division US20060235027A1 (en) 2000-07-28 2006-04-25 Inhibitors of cdc25 phosphatases

Publications (2)

Publication Number Publication Date
WO2002009686A2 WO2002009686A2 (fr) 2002-02-07
WO2002009686A3 true WO2002009686A3 (fr) 2003-10-09

Family

ID=8853011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/002443 Ceased WO2002009686A2 (fr) 2000-07-28 2001-07-26 Inhibiteurs de phosphatases cdc25

Country Status (19)

Country Link
US (3) US7196084B2 (fr)
EP (2) EP1602368A3 (fr)
JP (1) JP2004506618A (fr)
KR (1) KR20030020414A (fr)
CN (1) CN100406449C (fr)
AU (3) AU8223401A (fr)
BR (1) BR0112824A (fr)
CA (1) CA2417262A1 (fr)
CZ (1) CZ2003273A3 (fr)
FR (1) FR2812198B1 (fr)
HU (1) HUP0303828A3 (fr)
IL (2) IL153999A0 (fr)
IS (1) IS6701A (fr)
MX (1) MXPA03000860A (fr)
NO (1) NO20030421L (fr)
NZ (1) NZ523739A (fr)
PL (1) PL365074A1 (fr)
RU (1) RU2285521C2 (fr)
WO (1) WO2002009686A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812198B1 (fr) * 2000-07-28 2008-07-18 Sod Conseils Rech Applic DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25
ES2290359T3 (es) * 2001-12-27 2008-02-16 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivados de benzotiazol- y benzoxazol-4,7-diona y su utilizacion como inhibidores de fosfatasas cdc25.
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2879598B1 (fr) * 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
US20080208594A1 (en) * 2007-02-27 2008-08-28 Cross Charles W Effecting Functions On A Multimodal Telephony Device
FR2915747B1 (fr) * 2007-05-04 2011-02-25 Scras Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
RU2387635C1 (ru) * 2008-08-11 2010-04-27 Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (СО РАН) Фторированные производные 1,4-нафтохинона, обладающие цитотоксической активностью по отношению к раковым клеткам человека в культуре

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51146432A (en) * 1975-06-12 1976-12-16 Microbial Chem Res Found Process for preparation of benzanilide derivatives having therapeutic action to immunological disease
JPH0356431A (ja) * 1989-06-26 1991-03-12 Fujisawa Pharmaceut Co Ltd ジフェニル化合物
WO1995005363A1 (fr) * 1993-08-12 1995-02-23 Astra Aktiebolag Derives de l'amidine ayant des activites de synthetase de l'oxyde nitrique
WO1998042696A1 (fr) * 1997-03-24 1998-10-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
WO2000017190A2 (fr) * 1998-09-23 2000-03-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2193015A (en) * 1939-05-24 1940-03-12 Eastman Kodak Co Developer containing sulphonamide groups
US2652428A (en) * 1951-05-05 1953-09-15 Eastman Kodak Co N-alkyl-n-(beta-methylsulfonamidoethyl)-p-aminophenols
JPS525486B2 (fr) * 1973-02-13 1977-02-14
LU68988A1 (fr) * 1973-12-12 1975-08-20
US4032632A (en) * 1976-07-23 1977-06-28 Pfizer Inc. Mixture of antibiotics produced by new species of streptosporangium
FR2364204A1 (fr) * 1976-09-09 1978-04-07 Oreal Nouveaux metaaminophenols et compositions tinctoriales les contenant
AU567140B2 (en) * 1984-01-06 1987-11-12 Shionogi & Co., Ltd. Sulphonamido-benzamide derivatives
JPH0273068A (ja) * 1988-09-09 1990-03-13 Asahi Chem Ind Co Ltd 新規なフェネチルアミン誘導体及びその酸付加塩
JPH0844011A (ja) * 1994-07-29 1996-02-16 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5741819A (en) * 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
WO1997019682A1 (fr) * 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Derives aryle sulfonamide et sulfamide, et leurs utilisations
GB9800750D0 (en) * 1998-01-14 1998-03-11 Lilly Co Eli Pharmaceutical compound
FR2812198B1 (fr) * 2000-07-28 2008-07-18 Sod Conseils Rech Applic DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25
ES2290359T3 (es) * 2001-12-27 2008-02-16 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivados de benzotiazol- y benzoxazol-4,7-diona y su utilizacion como inhibidores de fosfatasas cdc25.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51146432A (en) * 1975-06-12 1976-12-16 Microbial Chem Res Found Process for preparation of benzanilide derivatives having therapeutic action to immunological disease
US4032635A (en) * 1975-06-12 1977-06-28 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pharmaceutical method for the therapy of immune diseases
JPH0356431A (ja) * 1989-06-26 1991-03-12 Fujisawa Pharmaceut Co Ltd ジフェニル化合物
WO1995005363A1 (fr) * 1993-08-12 1995-02-23 Astra Aktiebolag Derives de l'amidine ayant des activites de synthetase de l'oxyde nitrique
WO1998042696A1 (fr) * 1997-03-24 1998-10-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
WO2000017190A2 (fr) * 1998-09-23 2000-03-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"THE MERCK INDEX", 1996, MERCK & CO., INC, XP002166156 *
BOURHIM, MUSTAPHA ET AL: "Design, anticonvulsive, and neurotoxic properties of retrobenzamides. N-(nitrophenyl)benzamides and N-(aminophenyl)benzamides", ARZNEIM.-FORSCH. (1999), 49(2), 81-87, XP000992843 *
C. YAMAGAMI ET AL.: "A Quantitative Structure-Activity Study of Anticonvulsant Phenylacetanilides", HEM. PHARM. BULL., vol. 32, no. 12, 1984, pages 5003 - 5009, XP002166155 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FUJISAWA PHARMACEUTICAL CO., LTD., JAPAN: "Preparation of biphenyl compounds as drugs", XP002166157, retrieved from STN Database accession no. 115:114130 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; UMEZAWA, HAMAO ET AL: "Benzanilide derivatives", XP002166158, retrieved from STN Database accession no. 87:5662 *
R.A. COBURN ET AL.: "Potential Salicylamide Antiplaque Agents: In vitro Antibacterial Activity against Actinomyces viscosus", J. MED. CHEM., vol. 24, 1981, pages 1245 - 1249, XP000992845 *

Also Published As

Publication number Publication date
EP1602368A3 (fr) 2009-09-02
IL153999A (en) 2007-07-04
PL365074A1 (en) 2004-12-27
US20060235027A1 (en) 2006-10-19
AU2006233164B2 (en) 2008-10-23
CN1474689A (zh) 2004-02-11
HK1063016A1 (zh) 2004-12-10
AU2001282234B2 (en) 2006-07-27
FR2812198A1 (fr) 2002-02-01
US20040034103A1 (en) 2004-02-19
BR0112824A (pt) 2004-02-10
MXPA03000860A (es) 2003-06-06
CN100406449C (zh) 2008-07-30
KR20030020414A (ko) 2003-03-08
NO20030421L (no) 2003-03-19
CZ2003273A3 (cs) 2003-06-18
EP1370255A2 (fr) 2003-12-17
US20060154933A1 (en) 2006-07-13
WO2002009686A2 (fr) 2002-02-07
FR2812198B1 (fr) 2008-07-18
JP2004506618A (ja) 2004-03-04
RU2285521C2 (ru) 2006-10-20
US7196084B2 (en) 2007-03-27
IS6701A (is) 2003-01-27
HUP0303828A3 (en) 2007-10-29
EP1602368A2 (fr) 2005-12-07
HUP0303828A2 (hu) 2004-03-01
NZ523739A (en) 2005-09-30
IL153999A0 (en) 2003-07-31
AU8223401A (en) 2002-02-13
NO20030421D0 (no) 2003-01-27
AU2006233164A1 (en) 2006-11-09
CA2417262A1 (fr) 2002-02-07

Similar Documents

Publication Publication Date Title
CY1112130T1 (el) Ενεργοποιητης για υποδοχεα δελτα αποκρινομενος σε πολλαπλασιαστη υπεροξειδιοσωματος
HUP0000735A2 (hu) Az Xa faktort gátló nitrogéntartalmú heteroaromás vegyületek
HUP0400723A2 (hu) Izoxazolin-származékok és az azokat hatóanyagként tartalmazó herbicid készítmények
TR199701427T1 (xx) �nsektisidler olarak kullan�lan bisiklik aminler.
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
ATE239708T1 (de) Huperzin-derivate, ihre herstellung und ihre verwendung
EP1132376A4 (fr) Inhibiteurs de production/de secretion de proteine beta-amyloide
DK0742203T5 (da) Vitamin D-forbindelser og fremgangsmåde til fremstilling deraf
EA200300927A1 (ru) Новый способ промышленного синтеза тетрасложных эфиров 5-[бис(карбоксиметил)амино]-3-карбоксиметил-4-циано-2-тиофенкарбоновой кислоты и применение для синтеза бивалентных солей ранелиновой кислоты и их гидратов
HRP20030778B1 (hr) Bifenilkarboksamidi koji snižavaju lipide
HUP0402378A2 (hu) Gyulladáskeltő citokinokat gátló spirociklikus 6,7-dihidro-5H-pirazolo[1,2-a]pirazol-1-onok és az ezeket tartalmazó gyógyszerkészítmények
FI971227A0 (fi) Pyramidinyylipyratsolijohdannaisia
DE69724646D1 (de) 16-ene-vitamin d derivate
NO20050498L (no) CCK-1 reseptormodulatorer
IL166164A0 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
HUP9901621A2 (hu) Protein kináz C inhibitor hatású alkil-oxi-amino szubsztituenst tartalmazó fluorenon-származékok, alkalmazásuk, intermedierjeik és ezek előállítása, valamint a vegyületeket tartalmazó gyógyászati készítmények
YU43902A (sh) Novi razgranati supstituisani amino derivati od 3-amino-1- -fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
WO2003031404A3 (fr) Techniques de production d'isoxazoles et de 2-isoxazolines substituees
ECSP067004A (es) Formulación en aerosol para la inhalación de beta-agonistas
BG101267A (en) Bacteriacidal composition
EP0174685A3 (fr) Ethers herbicides
EA200200665A1 (ru) Новые соединения бензолсульфонамида, способ их получения и фармацевтические композиции, их содержащие
TW357056B (en) Herbicides
NO20030421L (no) Inhibitorer av Cdc25 fosfataser
DE60209887D1 (de) Primäre zwischenprodukte für die oxidative haarfärbung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 153999

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 523739

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2417262

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10343171

Country of ref document: US

Ref document number: 1020037001208

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/000860

Country of ref document: MX

Ref document number: PV2003-273

Country of ref document: CZ

Ref document number: 2001282234

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001960837

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2003105689

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: 018149545

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020037001208

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2003-273

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001960837

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 523739

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 523739

Country of ref document: NZ